Shire PLC (SHPG)

184.96
2.50 1.30
NASDAQ : Health Care
Prev Close 187.49
Open 187.58
Day Low/High 183.08 / 187.58
52 Wk Low/High 147.60 / 270.63
Volume 1.42M
Avg Volume 982.20K
Exchange NASDAQ
Shares Outstanding 302.37M
Market Cap 57.19B
EPS 1.30
P/E Ratio 51.40
Div & Yield 1.54 (0.80%)

Latest News

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

The study tested the drug on patients aged 12 years and older for 26 weeks.

Shire Continues 20-Year Commitment To ADHD With New Research At 2017 Annual Meeting Of American Psychiatric Association

Shire Continues 20-Year Commitment To ADHD With New Research At 2017 Annual Meeting Of American Psychiatric Association

Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD

Shire Granted EU Conditional Marketing Authorisation For Natpar[®¿] (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism

Shire Granted EU Conditional Marketing Authorisation For Natpar[®¿] (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire launches campaign to raise global awareness during World PI Week

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

European Stocks Mixed as Frankfurt Rises, Paris Falls

European Stocks Mixed as Frankfurt Rises, Paris Falls

The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients

Everything We Know About BioCryst's New HAE Drug

Everything We Know About BioCryst's New HAE Drug

BioCryst's Hereditary angioedema drug-trial results not compelling.

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Also up early Thursday: Bellicum and Novocure.

Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.